AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 21 min read$AVR

L1 Capital Pty Ltd purchased $3.0M of AVR (indirect holdings)

L1 Capital Pty Ltd purchased 397,226 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $7.62 ($7.60–$7.72, $3.03M total) across 2 trades over 2026-09-30 to 2026-10-01.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Oct 2, 2026, 12:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AVR
Bullish
high confidence
Mentioned
$AVR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRBullishLow
01

Why it matters

The $3M purchase increases the insider's stake, indicating confidence and possibly prompting other investors to buy.

02

Market read

Insider buying of a micro‑cap biotech can move the stock modestly; traders may watch for price reaction.

03

What to watch

Potential upcoming clinical data or regulatory events not disclosed could amplify the effect.

Relevance 7/10Novelty 6/10Timing: after-hours today

Background

Form 4 filings disclose insider transactions; L1 Capital Pty Ltd is a 10% owner of Anteris Technologies.

Company-level read

Ticker impact

$AVRBullishHigh confidence
Context

SEC Form 4 shows L1 Capital Pty Ltd bought 397,226 shares of Anteris Technologies (AVR) for $3.03M, increasing its stake to over 5.2M shares.

Expected impact

potential upward pressure as the market prices in the insider buying signal

Evidence & confidence

Form 4 filings are primary disclosures; a $3M purchase by a 10% owner is material for a micro‑cap biotech and can trigger buying interest.

Market effects

Sector

May signal confidence in Anteris' pipeline, modestly supportive for the biotech sector.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Low global impact; primarily relevant to AVR shareholders.

Counterpoint

What could challenge this read

The purchase could be a strategic stake without immediate operational impact; price may remain flat.

Key entities

  • company
    Anteris Technologies Global Corp.

    Biotech firm listed on Nasdaq under ticker AVR.

  • investor
    L1 Capital Pty Ltd

    10% owner of Anteris Technologies, executed the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AVR insider trading history →

Related articles

OCT 20
$AVRMedAI 8/10

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Anteris Technologies (ASX:AVR, NASDAQ:AVR) received German regulatory approval to expand its PARADIGM heart valve trial, allowing patient recruitment in Europe's largest market. The trial aims to enroll 1,000 patients to evaluate the DurAVR valve against existing devices. The company expects Germany's expertise to accelerate enrollment. DurAVR is a transcatheter heart valve designed to mimic a healthy aortic valve.

finance.yahoo.com2 min
OCT 20
$AVRMedAI 8/10

Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance

Anteris Technologies (NASDAQ: AVR, ASX: AVR) received regulatory clearance from Germany's BfArM to expand its PARADIGM Trial for the DurAVR® Transcatheter Heart Valve. This allows patient recruitment in Germany, Europe's largest TAVR market, accelerating trial enrollment. The PARADIGM Trial aims to evaluate the safety and effectiveness of DurAVR® compared to existing TAVRs.

stocktitan.net2 min